search
Back to results

A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer

Primary Purpose

Rectal Cancer

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Oxaliplatin, Capecitabine
Pre operative radiotherapy
Surgical Resection
Sponsored by
Royal Marsden NHS Foundation Trust
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rectal Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age over 18. Histological diagnosis of adenocarcinoma of rectum. Locally advanced/ poor prognosis primary rectal cancer defined by MRI criteria of any of the categories below; Tumour within 2 mm of mesorectal fascia ie circumferential resection margin threatened Any T3 tumour at/below levatores T3c tumour at any other level ie tumour extends >5 mm into peri-rectal fat T4 tumour Any T stage with 4 or more involved lymph nodes WHO performance status 0, 1 or 2. No evidence of metastatic disease as determined by CT scan of chest, abdomen, pelvis or other investigations such as PET scan or biopsy if required. Adequate bone marrow function with platelets > 100 X 109/l; WBC > 3 X 109/l; neutrophils > 1.5 X 109/l Normal renal function, with serum creatinine within the normal range or calculated creatinine clearance >50 ml/min. Adequate hepatic function with serum total bilirubin < 1.5 X upper limit of normal range. No concurrent uncontrolled medical conditions No previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix Adequate contraceptive precautions if relevant Informed written consent Exclusion Criteria: Medical or psychiatric conditions that compromise the patient's ability to give informed consent Presence of metastatic disease or recurrent rectal tumour Renal impairment (creatinine clearance<30 ml/min) Pregnancy or breast feeding Patients with a lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes Participation in any investigational drug study within the previous 4 weeks. Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia even if controlled with medication) or myocardial infarction within the last 12 months) Patients with any symptoms or history of peripheral neuropathy. Prior pelvic radiotherapy

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Pathological complete response rate.
    Acute toxicity has been evaluated in previous phase I studies and should occur to a similar extent.

    Secondary Outcome Measures

    Progression-free survival
    Treatment related toxicity
    Overall survival
    Radiological response rate
    Proportion of patients achieving pathological down staging compared with the pre-treatment MRI scan
    Surgical complications
    Bowel function and quality of life

    Full Information

    First Posted
    September 19, 2005
    Last Updated
    May 30, 2013
    Sponsor
    Royal Marsden NHS Foundation Trust
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00220051
    Brief Title
    A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer
    Official Title
    A Phase II Study of Oxaliplatin (Eloxatin) Capecitabine (Xeloda) and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2013
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2001 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Royal Marsden NHS Foundation Trust

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    To assess the efficacy and safety of pre-operative capecitabine and oxaliplatin followed by capecitabine with concurrent radiotherapy followed by post-operative capecitabine in the treatment of patients with locally advanced or inoperable rectal cancer.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Rectal Cancer

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    109 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Oxaliplatin, Capecitabine
    Intervention Type
    Procedure
    Intervention Name(s)
    Pre operative radiotherapy
    Intervention Type
    Procedure
    Intervention Name(s)
    Surgical Resection
    Primary Outcome Measure Information:
    Title
    Pathological complete response rate.
    Title
    Acute toxicity has been evaluated in previous phase I studies and should occur to a similar extent.
    Secondary Outcome Measure Information:
    Title
    Progression-free survival
    Title
    Treatment related toxicity
    Title
    Overall survival
    Title
    Radiological response rate
    Title
    Proportion of patients achieving pathological down staging compared with the pre-treatment MRI scan
    Title
    Surgical complications
    Title
    Bowel function and quality of life

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age over 18. Histological diagnosis of adenocarcinoma of rectum. Locally advanced/ poor prognosis primary rectal cancer defined by MRI criteria of any of the categories below; Tumour within 2 mm of mesorectal fascia ie circumferential resection margin threatened Any T3 tumour at/below levatores T3c tumour at any other level ie tumour extends >5 mm into peri-rectal fat T4 tumour Any T stage with 4 or more involved lymph nodes WHO performance status 0, 1 or 2. No evidence of metastatic disease as determined by CT scan of chest, abdomen, pelvis or other investigations such as PET scan or biopsy if required. Adequate bone marrow function with platelets > 100 X 109/l; WBC > 3 X 109/l; neutrophils > 1.5 X 109/l Normal renal function, with serum creatinine within the normal range or calculated creatinine clearance >50 ml/min. Adequate hepatic function with serum total bilirubin < 1.5 X upper limit of normal range. No concurrent uncontrolled medical conditions No previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix Adequate contraceptive precautions if relevant Informed written consent Exclusion Criteria: Medical or psychiatric conditions that compromise the patient's ability to give informed consent Presence of metastatic disease or recurrent rectal tumour Renal impairment (creatinine clearance<30 ml/min) Pregnancy or breast feeding Patients with a lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes Participation in any investigational drug study within the previous 4 weeks. Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia even if controlled with medication) or myocardial infarction within the last 12 months) Patients with any symptoms or history of peripheral neuropathy. Prior pelvic radiotherapy
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    D Cunningham
    Organizational Affiliation
    Royal Marsden NHS Foundation Trust
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    20106720
    Citation
    Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010 Mar;11(3):241-8. doi: 10.1016/S1470-2045(09)70381-X. Epub 2010 Jan 25.
    Results Reference
    derived

    Learn more about this trial

    A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer

    We'll reach out to this number within 24 hrs